Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 6, Pages 587-600
Publisher
Springer Science and Business Media LLC
Online
2020-03-12
DOI
10.1007/s40265-020-01285-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT)
- (2019) Vijay Viswanathan et al. Diabetes Technology & Therapeutics
- Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
- (2016) Tushar Madaan et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes
- (2014) A. P. Sykes et al. DIABETES OBESITY & METABOLISM
- The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
- (2014) Yu-nan Sun et al. BMJ Open
- Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
- (2014) Brian Irons et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
- (2013) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Diabetes in South Asians: Is the Phenotype Different?
- (2013) R. Unnikrishnan et al. DIABETES
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
- (2013) Alan Garber et al. Endocrine Practice
- Metformin: an old but still the best treatment for type 2 diabetes
- (2013) Lilian Beatriz Aguayo Rojas et al. Diabetology & Metabolic Syndrome
- First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
- (2013) Anita Kapur et al. BMC Pharmacology & Toxicology
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
- (2013) Tim Heise et al. Diabetes Therapy
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
- (2012) Muhammad A. Abdul-Ghani et al. Current Diabetes Reports
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
- (2011) R. L. Dobbins et al. DIABETES OBESITY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started